Vaccination has emerged as the most effective and economically viable medical discovery to improve public health. The use of vaccines has saved millions of lives globally.
Certain diseases such as smallpox, polio and measles have almost been eradicated through vaccination. Despite the remarkable success of vaccination against some types of disease, there are still remaining several infectious diseases for which vaccines are not yet available, including malaria, group A streptococcus (GAS), and human immunodeficiency virus (HIV).
Traditionally, most vaccine formulations consisted of live attenuated microorganisms or inactivated microorganisms. However, problems such as unwanted host reactions, reversion to virulence (especially in immunocompromised individuals) and difficulty in culturing the pathogenic microorganisms are often associated with the traditional vaccine approach.
The impracticality of traditional vaccines has resulted in the emergence of subunit vaccine that contains purified peptide antigens instead of the whole organisms or whole protein. Subunit vaccines peptide are generally safe to use as they do not possess the features of original pathogens. In the field of subunit vaccines, peptide-based antigens have been investigated extensively for our team in Peptidepharma Nova.
Peptide-based subunit vaccines are of great interest in modern immunotherapy as they are safe, easy to produce and well defined. However, remains a challenge that peptide antigens produce a relatively weak immune response, and thus require the use of immunostimulants (adjuvants) for optimal efficacy. In Peptidepharma Nova with new models and designs, peptidepharma has managed to optimize and immunopetential the immunological response of peptides at both the humoral and cellular levels. Peptidepharma offers this knowledge to its partners and joins the joint development with other partners for its transfer to clinical phases.
No products were found matching your selection.